Miguel Forte

The 18th Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice - Mariana Brandao https://lnkd.in/dNEG6yE4 Institut Jules Bordet #Cancer #CancerResearch #CancerTreatment #ADCs #ClinicalPractice #MedicalEvent #Symposium #Medicine #Health #Oncology #OncoDaily

21

🔔 𝐍𝐞𝐰 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐓𝐈𝐋-𝐁𝐚𝐬𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐚𝐧𝐝 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 We are happy to announce three significant publications in the field of cancer #immunotherapy from Oncologie | UNIL-CHUV. These studies provide new perspectives on the effectiveness of tumor-infiltrating lymphocyte (#TIL) therapy in advanced #melanoma, review the latest advances in adoptive cell therapy for lung cancer, and introduce a novel approach for investigating immune interactions in gastric cancer. 1. 𝐔𝐩𝐝𝐚𝐭𝐞𝐝 𝐌𝐞𝐭𝐚-𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐧 𝐓𝐈𝐋 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐦𝐞𝐥𝐚𝐧𝐨𝐦𝐚 https://lnkd.in/emm-RHYy Published in 𝘈𝘯𝘯𝘢𝘭𝘴 𝘰𝘧 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺, this comprehensive review and meta-analysis by George Coukos, John Haanen, Urania Dafni and colleagues re-examines the efficacy of TIL therapy for patients with advanced cutaneous melanoma, particularly within the current immuno-oncology landscape. The study presents a detailed analysis of overall survival (OS), objective response rate (ORR), and complete response rate (CRR), confirming that TIL therapy remains a valuable treatment option, even for patients who have previously undergone anti-PD-(L)1 therapy. This research reinforces TIL therapy's role as a potent second-line treatment, offering renewed hope for patients who did not respond to first-line immunotherapies. 2. 𝐑𝐞𝐯𝐢𝐞𝐰 𝐨𝐧 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐚𝐝𝐨𝐩𝐭𝐢𝐯𝐞 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 https://lnkd.in/etgMfkqj Published in 𝘊𝘢𝘯𝘤𝘦𝘳 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺, this review by George Coukos and colleagues explores the resurgence of TIL therapy for treating lung cancer, with a focus on recent clinical trials showing promising results in patients with advanced non-small cell lung cancer (NSCLC). The publication emphasizes the advancements in TIL therapy techniques and their potential to enhance existing immunotherapy approaches, representing a major step forward in the treatment of lung cancer. 3. 𝐓𝐮𝐦𝐨𝐫-𝐑𝐞𝐚𝐜𝐭𝐢𝐯𝐞 𝐓 𝐂𝐞𝐥𝐥 𝐜𝐥𝐨𝐧𝐨𝐭𝐲𝐩𝐞 𝐝𝐲𝐧𝐚𝐦𝐢𝐜𝐬 𝐢𝐧 𝐓𝐈𝐋 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 https://lnkd.in/eBsHnQav In a new study published in 𝘐𝘮𝘮𝘶𝘯𝘪𝘵𝘺, George Coukos, Alexandre Harari, Denarda Dangaj, Johanna Chiffelle, David Barras and colleagues tracked the clonotypes of tumor-reactive T cells in melanoma patients undergoing adoptive cell therapy (ACT) using TILs. This work sheds light on the dynamics of tumor-specific clonotypes from baseline through TIL expansion and post-transfer. The findings reveal that clinical responses are associated with the mobilization of tumor-resident CD8+ T cells, which reprogram during TIL expansion and reinvigorate upon engraftment in the tumor. ➡ more: https://lnkd.in/eeS7iSzX

46

1 Comment

🔊 Survey shows the positive impact of My Cancer Navigator on patients' lives! We are pleased to share the results of a survey conducted in collaboration with KU Leuven and Optigage | Tools and tailored services for healthcare, which highlights the valuable role of My Cancer Navigator in supporting cancer patients and their families. This personalized information service, offered by the Anticancer Fund, aims to empower patients by providing clear and reliable information about their diagnosis and treatment options. The survey, which gathered feedback from 109 users, revealed encouraging outcomes: 📊 86% of users gained a better understanding of their condition and treatments. 📊 72% reported feeling more emotionally supported. 📊 70% felt better equipped to cope with their diagnosis. 📊 52% mentioned changes in their disease management, including lifestyle adjustments. These findings confirm the importance of patient-centered information and underscore our commitment to continuously improve the service. We extend our gratitude to Jorn Hermans from KU Leuven, whose master’s thesis was dedicated to this survey, as well as Isabelle Huys , Rosanne Janssens, Manuel Bollue and Patrick Deroost , for their help in this important research. Read more here: https://lnkd.in/eawAeHFg #anticancerfund #mycancernavigator #patientempowerment Klara Rombauts Gabry Kuijten Liese Vandeborne Guy Buyens

26

3 Comments

September 1st marks World CLL Day. CLL (chronic lymphocytic leukemia) is the most common form of leukemia, yet it is still rare with about 600-1000 patients receiving the diagnosis each year in Belgium.    At AstraZeneca, we are dedicated to addressing the needs of patients by providing a platform that brings information and patients together to ensure support, information and connection.  🔗 https://lnkd.in/gJ3cGcdU 🔗 https://lnkd.in/gvGyf2YH   Together, we can make a difference in the lives of those affected by CLL. AZ BeLux,  from hope, to impact.   #WCLLD24 #LetsLevelUp #CLL #FromHopeToImpact https://www.wclld.org/

55

Europe is losing its competitive edge when it comes advanced therapies. We need to understand how we can collaborate more on a European level to be more interesting as a partner. This knowledge could help us complement each other rather than compete against each other. Read this article featuring insights from Daniel Gibson (Cell and Gene Therapy Catapult), Kristina Levan (ATMP Sweden) and Sylvie Ponchaut (BioWin). https://lnkd.in/eMJrSjdY

1

Interested in the current state of Belgium’s next generation therapies? Join us at Advanced Therapies in Belgium on October 15!     👉 Meet Stephane Petit at our shared booth with BeCRO, the Belgian Association of CROs to discuss the latest trends in clinical trial supplies and how we can help you optimise your clinical supplies strategy.    Clinigen Clinical Supplies Management Advanced Therapies in Belgium #clinicaltrialsupplies #clinicalsupplies #clinicaltrials

24

📢 Happy to inform you that the article on the launch event of our #LCWG has now been published in the Revue Médicale de Bruxelles - Volume 45 - n°2 ( link in comments) #multistakeholder #lungcancer #oncologie #AllCanBelgium

10

2 Comments

A key step forward in Organoid-Based Drug Screening - Nelson Dusetti Christophe Deben Edgar Cardenas De La Hoz Maxim Le Compte Sofie Seghers Evelien Smits https://lnkd.in/dpUh_2By #OncoDaily #Oncology #Cancer #Health #Medicine #CancerResearch

43

📢 Amplifying the Patient Voice in HTA: an Opportunity for Orphan Drug Manufacturers 📢 The influence of the patient voice in HTA decision-making was a key topic discussed at the World Orphan Drug Congress Europe in Barcelona last week. A keynote session on Day 2 highlighted that patient involvement can be particularly impactful in ultra-orphan disease indications, where evidence gaps are common due to small patient populations. Case studies where the patient voice made a significant impact on NICE decision-making were identified during the session: • Underestimated carer utility in an economic model for cystic fibrosis was amended following patient involvement with NICE. • The insatiable appetite of people with a rare genetic condition (condition not specified during the session) was uncovered during discussions between patients and NICE. This factor had not been included in the initial modelling presented to NICE and was consequently updated to include the impact of insatiable appetite in people with the condition. It is encouraging to see the tangible impact that incorporating Patient Experience Data into the HTA data package is having on NICE’s decision-making process. Incorporating the patient perspective can help manufacturers align with real-world experience, unmet needs and treatment preferences of patients to most effectively communicate the true value of their treatments to healthcare systems. At P4A we're committed to helping our clients effectively integrate patient voice into their HTA strategy. Through our RarePulse Social Media Listening offering, we can effectively gather patient insights to inform both the HTA and patient engagement strategy to enhance access outcomes for innovative therapies. To learn more about leveraging the patient voice throughout the development process, contact us today at [email protected]. Written by Beth McCormick, Senior Analyst #P4AInsights #MarketAccess #RareDiseases #PatientVoice #OrphanDrugs #SocialMediaListening #ThinkRare #RarePulse #NICE #WODC #PRMA #EconomicModelling #CostEffectiveness Link to the session: https://lnkd.in/e_etK54f

19

1 Comment

ᴄᴏɴᴄʟᴜsɪᴏɴs ᴏғ ᴛʜᴇ ᴀɴᴛᴡᴇʀᴘ ᴅᴇᴄʟᴀʀᴀᴛɪᴏɴ Following the adoption of the Council of the European Union Conclusions and the New Strategic Agenda 2024 – 2029, the call for competitiveness has been set high on the European🌍 agenda. We like to inform ℹ you that the conclusions of the Antwerp Dialogue on Biotech are now available. Have a look👀 at the conclusions on the @Antwerp Declaration website: 👉🏼 https://hubs.ly/Q02FNJDR0 This dialogue brought together different viewpoints and emphasised the need for a holistic, ecosystem approach to maximise potential of biotechnology and offered recommendations on: 💶 Mobilising capital and investments 📈 EU measures to stimulate market demand 👷‍♀️ Upskilling and workforce development 💡 Regulatory coherence and predictability 🔎 Scaling up and measuring success #proudtobestepg #IndustrialDeal #AntwerpDeclaration #greendeal #industry #europa #cefic

8

𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝗶𝘀 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵   At the 𝗕𝗲𝗹𝗴𝗶𝗮𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝘆, we are committed to closely monitoring cancer trends across the country. During this important month, we want to address a common concern we often hear: the perceived increase in breast cancer incidence among young women, as observed in several countries. 𝗜𝗻 𝗕𝗲𝗹𝗴𝗶𝘂𝗺, 𝘁𝗵𝗲 𝗱𝗮𝘁𝗮 𝘁𝗲𝗹𝗹𝘀 𝗮 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝘀𝘁𝗼𝗿𝘆. Our publication in BJMO (https://lnkd.in/eH5kUqVe) on early-onset cancers reveals a 𝘀𝗺𝗮𝗹𝗹 𝗯𝘂𝘁 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗱𝗲𝗰𝗿𝗲𝗮𝘀𝗲 in the risk of a breast cancer diagnosis for women under 50. Our most recent data shows a decline of 𝟬.𝟮% 𝗽𝗲𝗿 𝘆𝗲𝗮𝗿 between 2004 and 2022. While this is encouraging news, we must not forget that 𝟮𝟬𝟬𝟬 𝘄𝗼𝗺𝗲𝗻 𝗶𝗻 𝘁𝗵𝗶𝘀 𝗮𝗴𝗲 𝗴𝗿𝗼𝘂𝗽 are still diagnosed with breast cancer each year. This translates into a risk of 2.7% of getting a breast cancer diagnosis before the age of 50. As we raise awareness this month, it’s crucial to remember that behind every statistic is a person, and the fight for better outcomes continues. Let’s use October as a reminder to support research and stand together with those affected by breast cancer.    #BreastCancerAwareness #CancerRegistration #CancerResearch

30

Did you know that 60% of Belgians say they are ready to participate in a clinical study? On #WorldClinicalTrialDay, we are proud to unveil significant findings from our #survey in our new blog post. Dive into the data as we explore trends and insights on the behavior of Belgian people toward #clinicaltrials. #PatientEngagement #BelgianHealthcare EN: https://t.ly/o8OBA FR: https://t.ly/hXcLX NL: https://t.ly/vIknq

12

Today we celebrate #WorldClinicalTrialDay 🔬 Did you know that 60% of Belgians say they are ready to participate in a clinical study? Discover more insights on clinical trials in Curewiki's latest blog post. 💡

6

Caroline Ven underscores the industry’s commitment to ensuring uninterrupted #access to vital #treatments for Belgian patients. Much more topics in following Euractiv article: https://lnkd.in/eHNHAVQ6 #Health #medicines #vaccines #Belgium #België #Belgique #gezondheid #santé #patiënten #patients #innovation #innovatie #geneesmiddelen #médicaments EFPIA - European Federation of Pharmaceutical Industries and Associations AFMPS - Agence fédérale des médicaments et produits de santé

58

1 Comment

🩺 Are you looking to improve your understanding and ability to start a #biologic treatment, follow up with the #patient, and evaluate the success of treatment? EUFOREA hosted its first edition of the European Biologics Training Course on 1 March 2024 at the Académie royale de Médecine de Belgique in #brussels with more than 250 attendees worldwide. A hybrid training course designed to increase engagement and understanding of #biologics among healthcare professionals (ENT specialists, pulmonologists, and allergologists) treating patients with uncontrolled type 2 diseases including #asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Atopic Dermatitis (AD). Watch the European Biologics Training Course now and earn your #CME accreditation! 🔗 https://lnkd.in/ejmBkbn4 #eubiologics24 #health #healthcare #healthprofessionals #patients #patientcare #airwaydiseases #chronicdiseases #physicians #trainingcourse #trainingprogram #events2024 #nasalpolyps #asthmaawareness #treatment #ent #nonprofit #euforea #belgium #clinicians #pulmonologist #allergologist #atopicdermatitis #cmecredits

10

📢 New publication from Inovigate! 📢   Cancer remains a major health threat with over 70,000 annual diagnoses in Belgium. Innovative treatments like radioligand therapy (RLT), which targets cancer cells with radioactive substances, show very promising efficacy. Belgium, with its strong RLT legacy, has the potential to become a global leader in this field. However, effort and collaboration are necessary to sustain Belgium’s leading position and ensure Belgian patients benefit from the latest RLT advances. We are thrilled to unveil our latest policy report: "A Radioligand Therapy Action Plan for Belgium". This comprehensive plan, developed with insights from leading experts and co-created with all relevant stakeholders, outlines strategic steps and solutions to update cancer treatment in Belgium through the innovative use of radioligand therapies (RLTs). Multi-stakeholder discussions identified six major challenges for RLT readiness, and solutions have been devised with roles and responsibilities for authorities, healthcare professionals, and industrial partners.    The RLT action plan is not the end, but the beginning to pave the way to the best possible care. Today is the day we kicked off the implementation of the RLT action plan, during our RLT Symposium at NIHDI. Endorsed by all stakeholders, action groups were formed, and roles and responsibilities were divided, covering an RLT Hub, pricing & reimbursement, data registries, regulations, education & awareness and a clinical RLT framework.    Want to know more about the RLT action plan for Belgium and how we're ensuring patients get the best possible care? Read our report 👇 https://lnkd.in/eWUh9Dfq Interested in joining one of the action groups or want to know more? Feel free to contact us and join us in shaping the future of healthcare!🚀☢

39

"Belgium: Europe’s Hub for Life Sciences and Your Strategic Partner for Expansion" wrapped up at #BTS2024, spotlighting Belgium’s unmatched strengths as a premier life sciences hub. Key insights from the Consul General of Belgium and representatives from hub.brussels underscored Belgium’s strategic location, advanced research facilities, and thriving ecosystem. Delegates explored R&D grants, funding opportunities, and tax incentives, discovering how Belgium and India can collaborate to drive innovation and growth in health, biotech, and life sciences. #BTS2024 #BTSUnbound #BreakingBoundaries #BengaluruTechSummit

11